Xeris Biopharma Holdings, Inc. (XERS) Quality Score
Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Negative earnings, no valuation support
Above 30x, cash flow yield is thin
Above 10% CAGR, strong compounder
Recently turned FCF-positive, capex cycle finishing, CAGR not yet meaningful
Business Quality & Capital Allocation
Heavy dilution above 5%
Net debt/FCF of 3.0x, high leverage
Xeris Biopharma Holdings (XERS) quality: score, margins and returns
Xeris Biopharma Holdings (XERS) scores 30/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 4 metrics each scored 0 to 100. Every metric is computed from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Xeris Biopharma Holdings (XERS) a high-quality business?+
Xeris Biopharma Holdings scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Xeris Biopharma Holdings's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from XERS's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Xeris Biopharma Holdings scores well and where it falls behind.
How profitable is Xeris Biopharma Holdings?+
Xeris Biopharma Holdings runs a net margin of about -5.1%. Revenue has grown at roughly 70.2% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.
SourceQuality score computed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 7 Aug 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.